Medication Safety

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

Evidence > Medication Safety

Medication Safety
Complementary Medicine
Medicines Q & A
Drug Monitoring
(Reviews for Individual Funding Requests (IFRs))

475 library items in Medication Safety

Summaries of high quality independent reviews from nationally recognized bodies which either focus on the adverse effects caused by a particular medicine or group of medicines, or on interventions used to prevent or alleviate those adverse effects

Filter results by:

Date Published

Category

Results filtered by:

Area

Medication Safety (remove)

Sort by: Display summary:

Results 1 - 10 of 475

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Consensus guide on identification of potential high risk injectable medicines

Source: Medusa / UKMi,
Date published: 17/01/2012

Category:

Department of Health (DH) | Hospital pharmacy | National Patient Safety Agency (NPSA)

NeLM Area:

Evidence > Medication Safety

NPSA20_high_risk_consensus_list_Dec_2011_final_with_feedback.doc
2.

MHRA Drug Safety Update: Risk of hyperglycaemia and diabetes with statins

Source: MHRA,
Date published: 13/01/2012

Category:

2.12 Lipid-regulating drugs | Adverse Drug Reactions | Diabetes | Medicines and Healthcare products Regulatory Agency (MHRA)

NeLM Area:

Evidence > Medication Safety

Link

NPC Rapid Review (added 25/01/12)
3.

MHRA Drug Safety Update: Increases in blood pressure and heart rate with atomoxetine (Strattera®)

Source: MHRA,
Date published: 13/01/2012

Category:

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder | Adverse Drug Reactions | Attention deficit / hyperactivity disorder | Medicines and Healthcare products Regulatory Agency (MHRA)

NeLM Area:

Evidence > Medication Safety

Link

NPC Rapid Review (added 25/01/12)
4.

MHRA: Evidence does not suggest any link between use of angiotensin II receptor antagonists and cancer

Source: MHRA,
Date published: 13/12/2011

Category:

2.5.5 Drugs affecting the renin-angiotensin system | Adverse Drug Reactions | Cardiovascular Medicine | Medicines and Healthcare products Regulatory Agency (MHRA) | Oncology

NeLM Area:

Evidence > Medication Safety

Link
5.

MHRA: Need for renal function testing of patients receiving dabigatran (Pradaxa®)

Source: MHRA,
Date published: 13/12/2011

Category:

2.8.2 Oral anticoagulants | Adverse Drug Reactions | Medicines and Healthcare products Regulatory Agency (MHRA) | Venous Thromboembolism

NeLM Area:

Evidence > Medication Safety

Link
6.

MHRA: New data on QT interval prolongation with citalopram and escitalopram lead to changes in dose and cautions/contraindications

Source: MHRA,
Date published: 13/12/2011

Category:

4.3.3 Selective serotonin re-uptake inhibitors | Adverse Drug Reactions | Medicines and Healthcare products Regulatory Agency (MHRA) | Mental Health

NeLM Area:

Evidence > Medication Safety

Link
7.

Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis

Source: Cochrane Library,
Date published: 18/11/2011

Category:

4.7.3 Neuropathic pain | 10.1 Drugs used in rheumatic diseases and gout | 10.1.3 Drugs that suppress the rheumatic disease process | Ankylosing spondylitis | Drug reviews

NeLM Area:

Evidence > Medication Safety

Link to Abstract
8.

MHRA Drug Safety Update: Yellow cards which have made a difference – high dose rosuvastatin associated with increased risk of rhabdomyolysis

Source: MHRA,
Date published: 17/11/2011

Category:

2.12 Lipid-regulating drugs | Adverse Drug Reactions | Hyperlipidaemia | Medicines and Healthcare products Regulatory Agency (MHRA)

NeLM Area:

Evidence > Medication Safety

Link
9.

MHRA Drug Safety Update: Risk of second primary malignancy with use of lenalidomide (Revlimid) for newly diagnosed multiple myeloma

Source: MHRA,
Date published: 17/11/2011

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | Cancer: other | Medicines and Healthcare products Regulatory Agency (MHRA)

NeLM Area:

Evidence > Medication Safety

Link
10.

MHRA Drug Safety Bulletin “stop press” article: Paracetamol - reminder of updated dosing recommendations for children

Source: MHRA,
Date published: 17/11/2011

Category:

4.7.1 Non-opioid analgesics and compound analgesic preparations | Children (2-11 years) | Drugs in paediatrics | Infants (1-24 months) | Medicines and Healthcare products Regulatory Agency (MHRA)

NeLM Area:

Evidence > Medication Safety

Link

MHRA UK Public Assessment Report

Results 1 - 10 of 475

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next